Skip to main content
. 2019 Sep 5;4(17):e129856. doi: 10.1172/jci.insight.129856

Figure 2. PGRN supresses human NK cell activation.

Figure 2

PBMCs from healthy donors were pretreated with 100 μg/ml PGRN overnight and stimulated with K562 or 721.221 cells for 5 hours at an effector/target ratio of 10:1. The frequency of IFN-γ–producing and CD107a-expressing NK cells was determined by intracellular cytokine staining. (A and B) CD107a levels were measured in total NK cells (A) and CD56dim NK cells (B) by flow cytometry (n = 15). (C and D) IFN-γ levels in total NK cells (C) and CD56dim NK cells (D) were measured by flow cytometry (n = 15). Data in A–D show mean ± SEM. Each symbol represents experimental data from an individual healthy donor. P values calculated by paired Student’s t test; *P < 0.05; ***P < 0.001; ****P < 0.0001.